Pegozafermin Improves Fibrosis in NASH in Phase 2b Study
In the phase 2b ENLIVEN trial, the investigational drug pegozafermin met both primary endpoints at 24 weeks and led to improvements in fibrosis, paving the way for phase 3 development.
Medscape Medical News
source https://www.medscape.com/viewarticle/993798?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/993798?src=rss
Comments
Post a Comment